Antithrombin III synthesis in rat liver parenchymal cells

Léon, Martine; Aiach, Martine; Coëzy, E; Guennec, J.-Y. Le; Fiessinger, J N

doi:10.1016/0049-3848(83)90228-1

Cited by 28 publications

(14 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The diagnoses in the 57 patients were as follows: gastrointestinal cancer (16 patients), cholecystitis (12), diverticulitis (8), gastroduodenal ulcer (6), cholelithiasis (6), pancreatic cancer (2), colonic obstruction (2), splenomegaly for myeloproliferative disorders (2), adrenal cancer (l), uterin cancer (1) and acute necrotizing pancreatitis (1). The following surgical procedures were performed: colectomy (20 cases), cholecystectomy (18), gastrectomy (12), pancreatectomy (3), splenectomy (2), total hysterectomy (1) and adrenalectomy (1).…”

Section: Lo-mentioning

confidence: 99%

Evolution of antithrombin III during the postoperative period

Rodzynek¹,

Leautaud²,

Damien³

et al. 1984

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

In a prospective study, antithrombin I11 (AT 111) was performed preoperatively, peroperatively immediately after the surgical procedure and daily during the 8 postoperative days in 57 consecutive patients who underwent major abdominal surgery without prophylactic anticoagulant therapy. On d 8, according to the results of a bilateral radiological phlebography, the patients were divided into 2 groups: Group I: presence of deep venous thrombosis (DVT): n = 28 (49 %) and Group 2: absence of deep venous thrombosis: n = 29 (52 %). The results of the study showed that the preoperative AT I11 value did not constitute a marker of the postoperative DVT risk. During the postoperative period, AT I11 level decreased immediately following the intervention and resumed its preoperative value within 8 d. Nevertheless, this evolution was not different in the 2 groups and was not related to the presence of postoperative DVT.

show abstract

Section: Lo-mentioning

confidence: 99%

Evolution of antithrombin III during the postoperative period

Rodzynek¹,

Leautaud²,

Damien³

et al. 1984

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

show abstract

“…, 1979). AT is mainly synthesised in the liver (Leon et al. , 1985) with a normal plasma concentration of about 15 mg/dl (Chan et al.…”

Section: Introductionmentioning

confidence: 99%

“…It is a glycoprotein with a molecular weight of 58.000 Da and consists of 430 amino acids (Petersen et al, 1979). AT is mainly synthesised in the liver (Leon et al, 1985) with a normal plasma concentration of about 15 mg/dl (Chan et al, 1979). It inactivates thrombin as well as F Xa, IXa, XIa (Vinazzer, 1999).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a new immunoturbidimetric test (Liatest® antithrombin III) for determination of antithrombin antigen

Antović

Söderström

Karlman

et al. 2001

Clinical &Amp; Laboratory Haematology

View full text Add to dashboard Cite

Antithrombin (AT) is a glycoprotein mainly synthesised in the liver, and is one of the most important inhibitors of coagulation. Although AT activity determination is more important in clinical practice and anti-IIa and anti-Xa chromogenic tests are widely available, sometimes AT antigen measurement is preferred. Immunoradiometric and enzyme linked immunoabsorbent assay (ELISA) tests have been the only methods available so far for AT antigen determination, but both of them are relatively complicated, time consuming, and the ELISA test cannot be used for single sample assessment. A new immunoturbidimetric test (Liatest antithrombin III) is now available. We have adapted it for the Cobas Mira biomedical analyser. The intra- and inter-assay and total coefficients of variation for normal and low control plasma, as well as for normal pool plasma were low (< 3%). Blood samples from 32 patients with different clinical conditions were assessed both by the standard ELISA method and by the immunoturbidimetric method. The correlation coefficient was 0.95. According to our findings it seems that the immunoturbidimetric test (Liatest antithrombin III) for determination of AT antigen automated for the Cobas Mira biochemical analyser is easy to perform, time sparing and precise, with good comparability to other assays. It is suitable for measuring of AT antigen in routine laboratory work.

show abstract

“…The present case is the first novel splice-site mutation of SERPINC1 in a Korean family with inherited AT deficiency. Blood Coagul Fibrinolysis Introduction Antithrombin (AT) is synthesized predominantly by hepatocytes, has a half-life of approximately 2.4 days and a molecular weight of 58 kDa, and contains 432 amino acids [1,2]. AT is the major inhibitor of thrombin, factor IXa, and factor Xa in plasma and is also able to inactivate the other serine proteases of the intrinsic coagulation pathway, factors XIa and XIIa.…”

mentioning

confidence: 99%

A novel splice-site mutation c.42-2A>T (IVS1-2A>T) of SERPINC1 in a Korean family with inherited antithrombin deficiency

Jang

Lee²,

Chong³

et al. 2011

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Inherited antithrombin (AT) deficiency (OMIM 107300) is an autosomal dominant disorder and causes a 20-fold increase in the risk of venous thromboembolism. Herein, we describe a case of a novel splice-site mutation in the SERPINC1 gene in a Korean patient with inherited AT deficiency. The patient was a 35-year-old woman who presented with deep vein thrombosis (DVT) and pulmonary embolism and was without a recent history of any precipitating factors. The obtaining of her family history revealed that her mother had an ischemic stroke and a pulmonary embolism and her two sisters both had an episode of DVT during pregnancy. DNA sequencing of SERPINC1 revealed the novel variant IVS1-2A>T (c.42-2A>T), a substitution in intron 1, in the proband and her daughter. The mutation IVS1-2A>T eliminates the acceptor splice-site of intron 1. The present case is the first novel splice-site mutation of SERPINC1 in a Korean family with inherited AT deficiency.

show abstract

Antithrombin III synthesis in rat liver parenchymal cells

Cited by 28 publications

References 6 publications

Evolution of antithrombin III during the postoperative period

Evolution of antithrombin III during the postoperative period

Evaluation of a new immunoturbidimetric test (Liatest® antithrombin III) for determination of antithrombin antigen

A novel splice-site mutation c.42-2A>T (IVS1-2A>T) of SERPINC1 in a Korean family with inherited antithrombin deficiency

Contact Info

Product

Resources

About